Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Won Jin Jeon"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundDespite being the second leading cause of death in the United States, cancer disproportionately affects underserved communities due to multiple social factors like economic instability and limited healthcare access, leading to worse surviva
Externí odkaz:
https://doaj.org/article/b2a4d63c63fb45fe81c3f137db50fc1d
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTBackground: T-prolymphocytic leukemia (T-PLL) is an aggressive hematologic malignancy. A portion of patients can be cured with alemtuzumab induction followed by allogeneic hematopoietic stem cell transplant, but patients who relapse after tra
Externí odkaz:
https://doaj.org/article/2fab398806a24985a9f7976cb6305edf
Autor:
Won Jin Jeon, Bowon Joung, Jin Hyun Moon, Christopher Hino, Daniel Park, Bryan Pham, Dan Ran Castillo, Esther Chong, Simmer Kaur, Chanell Grismore, Huynh Cao
Publikováno v:
Hematology, Vol 28, Iss 1 (2023)
ABSTRACTObjectives Sickle cell disease (SCD) is characterized by a mutation in the beta-globin gene resulting in abnormal hemoglobin S (HgbS). The significant sequela of SCD include anemia and recurrent vaso-occlusive episodes (VOEs) which may effect
Externí odkaz:
https://doaj.org/article/f12fdf9da1114be0a2702a7d6eb4ca41
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Undifferentiated pleomorphic sarcoma (UPS), a subtype of soft tissue sarcoma (STS), is an uncommon malignancy associated with a poor prognosis. As with other forms of sarcoma, surgical resection remains the only form of treatment with curative potent
Externí odkaz:
https://doaj.org/article/09198af9a5424caf86f0ffb853df6fee
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The prognosis of sarcomatoid renal cell carcinoma has changed dramatically with the emergence of immune checkpoint inhibitors. Notably the use of nivolumab and ipilimumab combination therapy has demonstrated promising durable therapeutic response for
Externí odkaz:
https://doaj.org/article/d4ea5b149a52474c8480821047e9bc48
Publikováno v:
Frontiers in Oncology; 2024, p01-09, 9p
Autor:
Won Jin Jeon, Akhil Mehta, Jessica Hudson, Dani Ran Castillo, Jun Wang, Anthony Nguyen, Mojtaba Akhtari
Publikováno v:
The American Journal of the Medical Sciences. 365:457-461
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06e3ceb0b78b5befe0e7fda77f55e354
https://doi.org/10.1016/j.amjms.2023.01.002
https://doi.org/10.1016/j.amjms.2023.01.002
Autor:
Dani Ran Castillo, Won Jin Jeon, Carvy Floyd Luceno, Mark Bussell, Ron Coleman, Karla Pieters, Jamie Hankins, Annette Boggs, Lorena Garcia, Salem Dehom, Ellen D’Errico, Gayathri Nagaraj
Publikováno v:
Cancer Research. 83:P5-07
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent side effect of commonly used chemotherapy (CT) regimens and often results in dose reduction or cessation of treatment which can adversely affect cancer outcomes. Treatment opt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e3084e242cb7e6d8b70eb1fb66973cc
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-14
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-14
Autor:
Won Jin Jeon, Jasmine Nguyen, Dani Ran Castillo, Kiwon Park, Joel Brothers, Anthony Nguyen, Hamid Mirshahidi
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522211509
Introduction Pembrolizumab (Keytruda) is a monoclonal antibody against the programmed cell death-1 (PD-1) receptor on lymphocytes, which is one of the immune checkpoint inhibitors (ICIs) approved for multiple solid and hematologic malignancies. Altho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41e73720c40064be43c1d89988d911f5
https://doi.org/10.1177/10781552221150936
https://doi.org/10.1177/10781552221150936
Autor:
Seong Hee Choi, Muralidharan Mani, Jeonghwan Kim, Wha Ja Cho, Thomas F. J. Martin, Jee Hyun Kim, Hun Su Chu, Won Jin Jeong, Young-Wook Won, Byung Ju Lee, Byungyong Ahn, Junil Kim, Do Yong Jeon, Jeong Woo Park
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract More than half of tumor patients with high PD-L1 expression do not respond to anti-PD-1/PD-L1 therapy, and the underlying mechanisms are yet to be clarified. Here we show that developmentally regulated GTP-binding protein 2 (DRG2) is require
Externí odkaz:
https://doaj.org/article/5e550e5e56b94786a0359c3542a3191f